

JSC Active Management - Growth Strategy



Q2 '25 | As of 6.30.25

CHARACTERISTICS

Objective: JSC's Actively Managed Growth Portfolios are carefully tailored to each individual investor, for the purpose of capital appreciation. Growth Portfolios are designed to provide low beta, low downside capture, and consistent outperformance (defined as out performance over any 12 month period).

Methodology: A multi-asset strategy is deployed based on a framework developed by Andrew Graham, CFA over a 30 year timespan.


- **Investment selection** is done on a macro and micro level. Market internals, technical indicators, and broad economic conditions are utilized to identify key themes. Individual securities are then selected based on risk/reward and a combination of sell-side research and Main Street perspective.
- **Timing** is critical. Fundamentally attractive securities are bought at technically oversold levels when constructing a new portfolio, meaning all investments are not uniformly held across Growth Portfolios. Sell decisions are also made at the individual level, contributing to tax-efficient returns.
- **Protection** is as important as growth. Per-position loss limits are a key component of JSC's pragmatic approach to active management. Fees and taxes are limited in order to control two factors that degrade real returns.

Benchmark: 60% Russell 1000 Index, 20% Bloomberg Barclays US Aggregate Index, 20% MSCI EAFE (Net) Index

Total Assets in Strategy: \$349,871,602

HOLDINGS


Sector and Asset Class Distribution



PERFORMANCE

Growth of \$1,000,000 Net of Fees

JSC Growth Benchmark



Average Annual Total Returns (%) Net of Fees

	QTD	YTD	1yr	3yr	5yr	since inception*
JSC Growth	13.74%	4.85%	7.24%	18.24%	12.55%	13.17%
Russell 1000	11.11%	6.12%	15.66%	19.59%	16.30%	14.39%
Benchmark	9.26%	8.37%	14.31%	15.48%	11.90%	10.67%

*Inception date 5/1/2019.

TEN LARGEST HOLDINGS

NVIDIA Corp	CyberArk Software Ltd
Microsoft Corp	Apple Inc
Broadcom Inc	Berkshire Hathaway Inc Class B
Amazon.com Inc	Netflix Inc
Eli Lilly and Company	Spotify Technology SA

Top 10 as % of net total assets: 38.31%

CONTACT THE TEAM

(415) 854-5011

<https://jacksonsquarecap.com/>

Andrew Graham, CFA

Founder, Managing Partner
andrew@jacksonsquarecap.com

Michael Cordano

Investment Advisor
michael@jacksonsquarecap.com

Jack McRoskey

Investment Advisor
jack@jacksonsquarecap.com

Composite performance inception date 5/1/19; Data courtesy of Orion Advisor Solutions and Longs Peak Advisory Services. Investment advisory services provided through Jackson Square Capital, LLC an SEC registered investment adviser.

To learn more about Jackson Square Capital's Active Strategies visit <https://jacksonsquarecap.com/investment-management>

STRATEGY METRICS

Statistics Presented Net of Fees

	1yr				since inception			
	JSC Growth vs. R1000	R 1000	JSC Growth vs. Benchmark	Benchmark	JSC Growth vs. R1000	R1000	JSC Growth vs. Benchmark	Benchmark
Alpha (%)	(7.45)	0	(8.79)	0	0.30	0	2.01	0
Beta	0.91	1.00	1.18	1.00	0.87	1.00	1.06	1.00
St. Deviation	13.09	12.48	13.09	8.94	16.83	17.67	16.83	14.21
Sharpe Ratio	0.25	0.87	0.25	1.04	0.68	0.72	0.68	0.62
Upside Capture	0.67	1.00	0.87	1.00	0.90	1.00	1.12	1.00
Downside Capture	0.90	1.00	1.42	1.00	0.89	1.00	1.05	1.00
Max Drawdown	(9.76)	(7.99)	(9.76)	(3.76)	(30.35)	(24.59)	(30.35)	(23.08)

JSC GROWTH PORTFOLIOS IN ACTION

Largest Position Changes

Buys

Marvell Technology Inc NVIDIA Corp
Boston Scientific SPDR S&P 500 Trust
 Invesco Nasdaq 100 ETF Vertiv Hldg Co Class A

Sells

Apple Inc SPDR Gold Shares
 Mastercard Inc Howmet Aerospace Inc
 T-Mobile US Inc Com CAVA Group

Case Study: Boston Scientific Corp. (BSX)

Boston Scientific Corp. (BSX)

January 1, 2025 - June 30, 2025



Boston Scientific (BSX) chart courtesy of FactSet.

Boston Scientific's Farapulse Pulsed-Field Ablation (PFA) system has become a major growth driver, generating over \$1 billion in its first year post-FDA approval. This catalyst helped propel cardiovascular segment growth above 25% in Q1 2025, while overall company sales rose nearly 21% in the same quarter.

Despite facing \$200 million in tariff-related headwinds, Boston Scientific delivered a robust quarter and remains one of the few healthcare firms able to raise guidance amid ongoing geopolitical uncertainty. Management now projects 12.5%–14.5% reported revenue growth for 2025, underpinning strong cash flow, with free cash flow expected to surpass \$3 billion.

This combination of clinical innovation, operational execution, and resilience positions Boston Scientific as a high-conviction holding within our strategy emphasizing both growth themes and risk-aware, tax-efficient portfolio construction.

DISCLOSURES

This material is intended for informational purposes only. It should not be construed as legal or tax advice and is not intended to replace the advice of a qualified attorney or tax advisor. The information contained in this presentation has been compiled from third party sources and is believed to be reliable. All opinions and views constitute our judgments as of the date of writing, and are subject to change at any time without notice. This presentation is not an offer or solicitation to buy or sell securities and may not be construed as investment advice and does not give investment recommendations. The performance data quoted represents past performance and does not guarantee future results. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will either be suitable or profitable for a client or prospective client's investment portfolio. Historical performance results for investment indices and/or categories generally do not reflect the deduction of transaction and/or custodial charges, the deductions of an investment management fee, nor the impact of taxes, the incurrence of which would have the effect of decreasing historical performance results. The investment return and principal value of an investment will fluctuate; thus an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than return data quoted herein. An investor may experience loss of principal. Investment decisions always should be made based on the investor's specific financial needs and objectives, goals, time horizon, and risk tolerance. The asset classes and/or investment strategies described may not be suitable for all investors, and investors should consult with an investment advisor to determine the appropriate investment strategy.

Investments in smaller companies carry greater risk than is customarily associated with larger companies for various reasons, such as volatility of earnings and prospects, higher failure rates, and limited markets, product lines, or financial resources. Investing overseas involves special risks, including the volatility of currency exchange rates and, in some cases, limited geographic focus, political and economic instability, and relatively illiquid markets. Income (bond) securities are subject to interest rate risk, which is the risk that debt securities in a portfolio will decline in value because of increases in market interest rates. Exchange Traded Funds (ETFs) are subject to risks similar to those of stocks, such as market risk. Investing in ETFs may bear indirect fees and expenses charged by ETFs in addition to their direct fees and expenses, as well as indirectly bearing the principal risks of those ETFs. ETFs may trade at a discount to their net asset value, and are subject to the market fluctuations of their underlying investments. Investing in commodities can be volatile, can suffer from periods of prolonged decline in value, and may not be suitable for all investors. Index performance is presented for illustrative purposes only, and does not represent the performance of any specific investment product or portfolio. An investment cannot be made directly into an index.

Jackson Square Capital, LLC's composite performance results reflect time-weighted rates of returns of a composite of actual portfolios which have traded equities, ETFs, bonds, and other securities based upon the Firm's proprietary trading strategies. Whenever possible, we attempt to use accounts with no additions or withdrawals. Accounts are excluded from the composite according to our Account Exclusion Policy. Results from these excluded accounts may differ substantially from the composite. Included accounts for the calculation of the composite return are accounts we believe to be historically representative of the portfolio strategy during the corresponding time period with a minimum account size of \$100,000. Performance results reflect the deduction of transaction fees and a model management fee of 1.00%. The Russell 1000 is presented in the average annual total returns and strategy metrics tables as an additional benchmark for comparison purposes.

CONTACT THE TEAM

(415) 854-5011

<https://jacksonsquarecap.com/>

Andrew Graham, CFA

Founder, Managing Partner
 andrew@jacksonsquarecap.com

Michael Cordano

Investment Advisor
 michael@jacksonsquarecap.com

Jack McRoskey

Investment Advisor
 jack@jacksonsquarecap.com

Data courtesy of Orion Advisor Solutions.

Investment advisory services provided through Jackson Square Capital, LLC an SEC registered investment adviser.

To learn more about Jackson Square Capital's Active Strategies visit <https://jacksonsquarecap.com/investment-management/>